COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF SPIRINOLACTONE AND EPLERENONE IN PATIENTS WITH DIFFERENT LEFT VENTRICULAR EJECTION FRACTION IN CHRONIC HEART FAILURE.
Article Sidebar
Main Article Content
Аннотация:
In the article, the scientific literature confirming the effect of spirinolactone and eplerenone, belonging to the group of mineralocorticoid receptor antagonists, on the quality of life, the number of hospitalizations, the outcome of the disease, and the length of life of patients with chronic heart failure was studied, and the effects of these two drugs were comparatively evaluated.
Article Details
Как цитировать:
Библиографические ссылки:
2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives, Heidenreich PA, Bozkurt B, Aguilar D, et al. J Am Coll Cardiol. 2022 May, 79 (17) e263–e421.
Gianluigi savarese and Lars H Lund, Department of Medicine, Cardiology Unit, Karolinska Institutet, FoU Tema Hjarta och Karl, S1:02, 17176 Stockholm, Sweden. E: 2017, Radcliffe Cardiology.
González A, Ravassa S, López B, Moreno MU, Beaumont J, José GS, et al. Myocardial Remodeling in Hypertension. Hypertension (Dallas, Tex: 1979). 2018;72:549–58.
Khan, M.H., Gerson, M.C. Use of mineralocorticoid receptor antagonist in ST elevation myocardial infarction. J. Nucl. Cardiol. 29, 2336–2339 (2022).
King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am fam Physician. 2020 Jun 15;85(12):1161-8.
Kirichenko A.A. Cardioprotective effect of eplere- none. Consilium Medicum. 2018;20 (1): 15–20. Russian (Кириченко А. А. Кардиопротективные эффекты эплеренона. Consilium Medicum. 2018;20 (1): 15–20). DOI: 10.26442/2075.
Komajda M, Isnard R, Cohen-Solal A, et al. Effect of spirinolactone in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017; 19:1495–1503.
Kovesdy C.P., Matsushita K., Sang Y. et al. CKD Prognosis Consortium. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535–42. DOI: 10.1093.
Maryam Nabati MD Person Envelope Sasan Tabiban MD Afshin Khani MD Jamshid Yazdani MD Hamideh. The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial. Sep, 2021.
Matthew S. Durstenfeld, Stuart D. Katz, Hannah Park&Saul Blecker, 2019; Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study.
Md. Noornabikhon Dokar, Khurshed Ahmed, Mohammad Ashraf Hossain Comparison between Spironolactone and Eplerenone on LV Systolic Function in Patients with Chronic Heart Failure.2, July 2020
Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. The lancet. Lancet Diabet Endocrinol. 2018;6:41–50.
Polyakov D. S., Fomin I. V., Belenkov Yu. N., Mareev V. Yu., Ageev F.T., Artemyeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow- up? Results of the EPOCH-CHF study. Cardiology. 2021;61 (4): 4–14. Russian (Поляков Д.С., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследова- ния ЭПОХА–ХСН. Кардиология. 2021;61
Toda K, Kasama S, Toyama T, Kasahara M, Kurabayashi M. Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. J Nucl Cardiol 2021.
Tsai, CH., Pan, CT., Chang, YY. et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens 35, 131–147 (2021).
Zhang M, Zhu P, Wang Y, Wu J, Yu Y, Wu X, et al. Bilateral sympathetic stellate ganglionectomy attenuates myocardial remodelling and fibrosis in a rat model of chronic volume overload. J Cell Mol Med 2019;23:1001-13.
Zhou M, Liu Y, Xiong L, Quan D, He Y, Tang Y, et al. Cardiac sympathetic afferent denervation protects against ventricular arrhythmias by modulating cardiac sympathetic nerve activity during acute myocardial infarction. Med Sci Monit 2019;25:1984-93.
Коваленко Е.В., Маркова Л.И., Белая О.Л. Антагонисты минералокортикоидных рецепторов в лечении больных с хронической сердечной недостаточностью: доказанная эффективность и перспективные возмож- ности. Международный журнал сердца и сосудистых заболеваний. 2022; 10 (34): 33–43.